T. Rowe Price Associates’s Tarsus Pharmaceuticals TARS Stock Holding History

T. Rowe Price Associates’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.3M	Sell	274,804 -243,976	-47%	-$17M	﹤0.01%	1048
2025 Q4	$42.5M	Buy	518,780 +65,923	+15%	+$4.92M	﹤0.01%	855
2025 Q3	$26.9M	Buy	452,857 +68,955	+18%	+$3.39M	﹤0.01%	985
2025 Q2	$15.6M	Sell	383,902 -49,269	-11%	-$2.22M	﹤0.01%	1011
2025 Q1	$22.3M	Sell	433,171 -27,602	-6%	-$1.36M	﹤0.01%	932
2024 Q4	$25.5M	Buy	460,773 +221,458	+93%	+$10.1M	﹤0.01%	933
2024 Q3	$7.87M	Sell	239,315 -51,960	-18%	-$1.46M	﹤0.01%	1185
2024 Q2	$7.92M	Sell	291,275 -56,408	-16%	-$1.9M	﹤0.01%	1144
2024 Q1	$12.6M	Buy	+347,683	New	+$10.2M	﹤0.01%	1063

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's TARS Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Tarsus Pharmaceuticals (TARS) stake by 47% in Q1 2026, selling an estimated $17M and leaving 274,804 shares worth $19.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1048.

T. Rowe Price Associates first reported a position in TARS in Q1 2024 and has held it in 9 quarters since. The position peaked at $42.5M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

T. Rowe Price Associates held 274,804 shares of Tarsus Pharmaceuticals worth $19.3M as of Q1 2026.
T. Rowe Price Associates sold 243,976 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $17M.
Tarsus Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1048 holding.
T. Rowe Price Associates first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
T. Rowe Price Associates's Tarsus Pharmaceuticals position peaked at $42.5M in Q4 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.